Suppr超能文献

“德国模式”用于阿片类药物转换为口服左美沙酮的实用性、安全性和有效性。

Practicability, safety, and efficacy of a "German model" for opioid conversion to oral levo-methadone.

机构信息

Division of Palliative Medicine, University of Erlangen, Erlangen, Germany.

出版信息

Support Care Cancer. 2012 Sep;20(9):2105-10. doi: 10.1007/s00520-011-1320-8. Epub 2011 Dec 1.

Abstract

INTRODUCTION

An algorithm to convert from any other opioid to oral levo-methadone was developed in Germany, the German model of levo-methadone conversion (GMLC). According to this GMLC, the pre-existing opioid is stopped, then titration of oral levo-methadone is initiated with a starting dose of 5 mg orally q 4 h (plus prn q 1 h). If necessary, levo-methadone dose is increased (pain) or decreased (side effects) by 30% q 4 h (plus prn q 1 h). After 72 h, the achieved single dose is maintained, but the dosing interval increases twofold to q 8 h (plus prn q 3 h). The aim of this study was to obtain information about the practicability, safety, and efficacy of the GMLC in clinical routine.

METHODS

A retrospective, systematic chart review of levo-methadone conversions for the treatment of pain in inpatient palliative care was performed.

RESULTS

Fifty-two patients were analyzed. The dosing interval was increased correctly after 72 h as demanded by the GMLC in 60% of patients. In 85% of the patients, opioid medication with levo-methadone could be maintained until the end of the inpatient stay. In three patients (6%), levo-methadone administration had to be stopped due to side effects. No serious adverse events could be detected during opioid rotation. Pain intensity was reduced significantly (p < 0.001) after conversion concerning mean (NRS 0.9; range 0-4) and maximum pain over the day (NRS 3.9; range 0-10).

CONCLUSION

The presented study indicates that the GMLC provides a practical and reasonably safe approach to perform opioid rotation to levo-methadone in a palliative care setting.

摘要

简介

德国开发了一种将其他阿片类药物转换为口服左美沙酮的算法,即德国左美沙酮转换模式(GMLC)。根据该 GMLC,停止使用现有的阿片类药物,然后开始以 5 毫克口服 q4h(按需加 prn q1h)的起始剂量滴定口服左美沙酮。如果需要,左美沙酮剂量增加(疼痛)或减少(副作用)30% q4h(按需加 prn q1h)。72 小时后,维持达到的单剂量,但将给药间隔增加一倍至 q8h(按需加 prn q3h)。本研究旨在获得关于 GMLC 在临床常规中实用性、安全性和疗效的信息。

方法

对姑息治疗住院患者疼痛治疗中左美沙酮转换的回顾性、系统病历回顾。

结果

分析了 52 名患者。60%的患者正确地按照 GMLC 的要求在 72 小时后增加了给药间隔。85%的患者可以用左美沙酮维持阿片类药物治疗直到住院结束。3 名患者(6%)因副作用不得不停止使用左美沙酮。在阿片类药物转换过程中未发现严重不良事件。转换后疼痛强度显著降低(p<0.001),平均 NRS(0.9;范围 0-4)和日间最大 NRS(3.9;范围 0-10)。

结论

本研究表明,GMLC 为在姑息治疗环境中进行阿片类药物转换为左美沙酮提供了一种实用且相对安全的方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验